Alzinova AB (publ) (ALZ.ST)
SEK 2.02
(1.46%)
SEK 2.02
(1.46%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 9.33 Million SEK | 53.27% |
| 2022 | 6.08 Million SEK | 89.09% |
| 2021 | 3.21 Million SEK | -32.81% |
| 2020 | 4.79 Million SEK | 8.4% |
| 2019 | 4.42 Million SEK | 89.33% |
| 2018 | 2.33 Million SEK | 0.26% |
| 2017 | 2.32 Million SEK | 64.85% |
| 2016 | 1.41 Million SEK | -9.79% |
| 2015 | 1.56 Million SEK | 165.74% |
| 2014 | 589.25 Thousand SEK | -19.06% |
| 2013 | 728.02 Thousand SEK | 328.8% |
| 2012 | 169.78 Thousand SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 8.17 Million SEK | -12.41% |
| 2024 Q2 | 8.37 Million SEK | 2.52% |
| 2023 Q2 | 4.59 Million SEK | -20.75% |
| 2023 Q3 | 7.73 Million SEK | 68.24% |
| 2023 Q4 | 9.33 Million SEK | 20.57% |
| 2023 FY | 9.33 Million SEK | 53.27% |
| 2023 Q1 | 5.8 Million SEK | -4.66% |
| 2022 FY | 6.08 Million SEK | 89.09% |
| 2022 Q4 | 6.08 Million SEK | 29.79% |
| 2022 Q1 | 8.32 Million SEK | 158.5% |
| 2022 Q2 | 4.06 Million SEK | -51.15% |
| 2022 Q3 | 4.69 Million SEK | 15.38% |
| 2021 FY | 3.21 Million SEK | -32.81% |
| 2021 Q3 | 3.18 Million SEK | -48.97% |
| 2021 Q2 | 6.24 Million SEK | -3.17% |
| 2021 Q4 | 3.21 Million SEK | 1.0% |
| 2021 Q1 | 6.45 Million SEK | 34.63% |
| 2020 Q3 | 3.25 Million SEK | -27.68% |
| 2020 Q4 | 4.79 Million SEK | 47.23% |
| 2020 FY | 4.79 Million SEK | 8.4% |
| 2020 Q1 | 5.12 Million SEK | 16.04% |
| 2020 Q2 | 4.5 Million SEK | -12.27% |
| 2019 Q3 | 2.37 Million SEK | -18.91% |
| 2019 Q1 | 3 Million SEK | 28.75% |
| 2019 FY | 4.42 Million SEK | 89.33% |
| 2019 Q4 | 4.42 Million SEK | 85.76% |
| 2019 Q2 | 2.93 Million SEK | -2.38% |
| 2018 Q3 | 3.98 Million SEK | 32.72% |
| 2018 FY | 2.33 Million SEK | 0.26% |
| 2018 Q2 | 3 Million SEK | 28.73% |
| 2018 Q1 | 2.33 Million SEK | 0.09% |
| 2018 Q4 | 2.33 Million SEK | -41.37% |
| 2017 Q1 | 1.58 Million SEK | 12.22% |
| 2017 FY | 2.32 Million SEK | 64.85% |
| 2017 Q4 | 2.32 Million SEK | 0.44% |
| 2017 Q3 | 2.31 Million SEK | 1.46% |
| 2017 Q2 | 2.28 Million SEK | 44.14% |
| 2016 FY | 1.41 Million SEK | -9.79% |
| 2016 Q3 | 1.66 Million SEK | 18.32% |
| 2016 Q2 | 1.4 Million SEK | 6.99% |
| 2016 Q1 | 1.31 Million SEK | -16.13% |
| 2016 Q4 | 1.41 Million SEK | -15.03% |
| 2015 Q1 | - SEK | -100.0% |
| 2015 FY | 1.56 Million SEK | 165.74% |
| 2015 Q4 | 1.56 Million SEK | 0.0% |
| 2014 FY | 589.25 Thousand SEK | -19.06% |
| 2014 Q4 | 589.25 Thousand SEK | 0.0% |
| 2013 FY | 728.02 Thousand SEK | 328.8% |
| 2012 FY | 169.78 Thousand SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Active Biotech AB (publ) | 13.4 Million SEK | 30.366% |
| Biovica International AB (publ) | 34.76 Million SEK | 73.161% |
| Cantargia AB (publ) | 54.97 Million SEK | 83.025% |
| CombiGene AB (publ) | 4.15 Million SEK | -124.519% |
| Cyxone AB (publ) | 4.69 Million SEK | -98.786% |
| Diagonal Bio AB (publ) | 7.26 Million SEK | -28.526% |
| Elicera Therapeutics AB (publ) | 13.77 Million SEK | 32.244% |
| ExpreS2ion Biotech Holding AB (publ) | 13.32 Million SEK | 29.989% |
| Fluicell AB (publ) | 8.91 Million SEK | -4.666% |
| Infant Bacterial Therapeutics AB (publ) | 46.18 Million SEK | 79.794% |
| Mendus AB (publ) | 51.22 Million SEK | 81.784% |
| Isofol Medical AB (publ) | 19.16 Million SEK | 51.31% |
| I-Tech AB | 16.2 Million SEK | 42.419% |
| Intervacc AB (publ) | 21.68 Million SEK | 56.96% |
| Lipigon Pharmaceuticals AB (publ) | 5.15 Million SEK | -80.903% |
| Magle Chemoswed Holding AB (publ) | 123.97 Million SEK | 92.474% |
| Modus Therapeutics Holding AB (publ) | 2.35 Million SEK | -295.549% |
| OncoZenge AB (publ) | 1.69 Million SEK | -449.205% |
| Sprint Bioscience AB (publ) | 34.6 Million SEK | 73.034% |
| Xbrane Biopharma AB (publ) | 482.17 Million SEK | 98.065% |
| Lipum AB (publ) | 7.53 Million SEK | -23.786% |
| Alligator Bioscience AB (publ) | 106.59 Million SEK | 91.246% |
| Ziccum AB (publ) | 6.38 Million SEK | -46.071% |
| BioArctic AB (publ) | 139.5 Million SEK | 93.311% |
| Genovis AB (publ.) | 98.04 Million SEK | 90.483% |
| Camurus AB (publ) | 414.81 Million SEK | 97.751% |
| IRLAB Therapeutics AB (publ) | 61.35 Million SEK | 84.792% |
| Bio-Works Technologies AB (publ) | 16.11 Million SEK | 42.105% |
| Aptahem AB (publ) | 8.99 Million SEK | -3.703% |
| Vicore Pharma Holding AB (publ) | 40.85 Million SEK | 77.163% |
| Xspray Pharma AB (publ) | 71.85 Million SEK | 87.013% |
| Kancera AB (publ) | 17.97 Million SEK | 48.098% |
| Saniona AB (publ) | 86.08 Million SEK | 89.16% |
| Spago Nanomedical AB (publ) | 11.66 Million SEK | 20.029% |
| AcouSort AB (publ) | 10.37 Million SEK | 10.089% |
| Xintela AB (publ) | 14.01 Million SEK | 33.421% |
| Abliva AB (publ) | 16.78 Million SEK | 44.395% |
| Karolinska Development AB (publ) | 11.56 Million SEK | 19.345% |
| Amniotics AB (publ) | 10.54 Million SEK | 11.529% |
| 2cureX AB (publ) | 2.93 Million SEK | -217.922% |
| Asarina Pharma AB (publ) | 4.42 Million SEK | -110.822% |
| Calliditas Therapeutics AB (publ) | 1.56 Billion SEK | 99.404% |
| Hansa Biopharma AB (publ) | 1.18 Billion SEK | 99.213% |
| Biosergen AB | 5.08 Million SEK | -83.5% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 26.7 Million SEK | 65.063% |
| Corline Biomedical AB | 6.78 Million SEK | -37.443% |
| NextCell Pharma AB | 13.68 Million SEK | 31.836% |
| Nanologica AB (publ) | 79.32 Million SEK | 88.237% |
| LIDDS AB (publ) | 3.75 Million SEK | -148.429% |
| Egetis Therapeutics AB (publ) | 214.6 Million SEK | 95.652% |
| BioInvent International AB (publ) | 90.45 Million SEK | 89.684% |
| SynAct Pharma AB | 51.83 Million SEK | 81.998% |
| Annexin Pharmaceuticals AB (publ) | 7.94 Million SEK | -17.386% |
| Stayble Therapeutics AB (publ) | 5.19 Million SEK | -79.617% |
| Ascelia Pharma AB (publ) | 12.74 Million SEK | 26.781% |
| Oncopeptides AB (publ) | 181.59 Million SEK | 94.862% |
| Pila Pharma AB (publ) | 1.79 Million SEK | -420.123% |
| Guard Therapeutics International AB (publ) | 18.49 Million SEK | 49.546% |
| Scandinavian ChemoTech AB (publ) | 3.83 Million SEK | -143.121% |
| Simris Alg AB (publ) | 148.93 Million SEK | 93.735% |
| Diamyd Medical AB (publ) | 71.11 Million SEK | 86.88% |